FDA Companion, Co-Development Dx Guidances On Track, Official Says

FDA aims to issue both a final companion diagnostics guidance document and a separate draft guidance on the co-development of drugs and tests in the coming months.

FDA hopes to issue a draft guidance on co-development of drugs and diagnostics by “late summer,” according to Elizabeth Mansfield, the top personalized medicine official at CDRH.

The planned guidance is a follow-up effort to draft guidelines released last July providing FDA’s definition of a companion diagnostic...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

More from Policy & Regulation